Gemcitabine and Reactivation of Hepatitis B

Medical Oncology

Volumn 20, Issue 4, 2003, Pages 385-387

  Cheong, Kerry ^a   Li, Jordan ^a   Karapetis, Christos Stelios ^a,b  

^a FLINDERS MEDICAL CENTRE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

Author keywords

Chemotherapy; Gemcitabine; Hepatitis B; Lamivudine

Indexed keywords

GEMCITABINE; LAMIVUDINE; VIRUS DNA;

AGED; ARTICLE; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CASE REPORT; CELLULAR IMMUNITY; CHRONIC HEPATITIS; CLINICAL FEATURE; DISEASE COURSE; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN TISSUE; INFECTION RISK; LIVER FUNCTION; LUNG CARCINOMA; PALLIATIVE THERAPY; PATIENT MONITORING; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS REACTIVATION;

AGED; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HUMANS; LIVER FUNCTION TESTS; PLEURAL NEOPLASMS; RECURRENCE;

EID: 0346102827     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:20:4:385     Document Type: Article

References (9)

1. Lok ASF, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Gastroenterology 1991;100(1):182-188.
2. Liang R, Lau GKK, Kwong YL. Chemotherapy and bone marrow transplantation for cancer patients who are also chronic hepatitis B carrier: a review of the problem. J. Clin. OncoL. 1999;17(1):394-398.
3. Perrillo RP. Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001;120(3):1009-1022.
4. Yeo W, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. Proc Am Soc Clin Oncol 2000;19:600a (abstr 2361).
5. Yeo W, et al. Lamivudine prevents hepatitis B virus (HBV) reactivation in HBV carriers undergoing cytotoxic chemotherapy (CT) - a prospective study. Proc Am Soc Clin Oncol 2002;21:362a (abstr 1447).
6. Alvino E, Fuggetta MP, Tricarico M, Bonmassar E. 2′-2′- Difluorodeoxycytidine: in vitro effects on cell-mediated immune response. Anticancer Res 1998;18(5A):3597-3602.
7. Mok TSK, et al. A phase II study of gemcitabine plus oral etoposide in the treatment of patients with advanced non-small cell lung carcinoma. Cancer 2000;89(3):543-550.
8. Fischer DS, Knobf MT, Durivage HJ. Chemotherapy drugs. In: Fischer DS (ed). The Cancer Chemotherapy Handbook, 5th ed. Mosby: St Louis, 1997, p. 128.
9. Noble S, Goa KL. Gemcitabine: a review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 1997;54(3):447-472.